Published • loading... • Updated
Moderna Cancer Vaccine Stops Melanoma Returning: What’s Next for Personalized Treatments?
The companies said the vaccine cut the risk of recurrence by 50% and spread by 59% in a prior mid-stage trial.
- On Wednesday, Moderna and Merck announced their personalized mRNA vaccine helped prevent melanoma recurrence in a large trial involving more than 1,000 patients who had localized tumors surgically removed.
- Their treatment, intismeran autogene, combines a customized mRNA vaccine with Merck's immunotherapy drug Keytruda to train the immune system to specifically target mutations found only on a patient's tumor cells.
- The study enrolled around 1,100 people with advanced melanoma; previous mid-stage trial data showed the vaccine cut the risk of cancer returning by half and reduced spread risk by 59 per cent compared with Keytruda alone.
- Dr. Julie Gralow, chief medical officer of the American Society of Clinical Oncology, called the results "a monumental leap forward," while Dr. Elizabeth Buchbinder, a melanoma specialist at the Mass General Brigham Cancer Institute, said it "may change that math" for treatment.
- Researchers are investigating potential applications for other cancers, with colon cancer trial results expected in 2027 and pancreatic cancer trials following in 2031.
Insights by Ground AI
Podcasts & Opinions
11 Articles
11 Articles
How Moderna's personalised cancer vaccine trains the body to hunt down tumours
Moderna and Merck's personalised mRNA cancer vaccine met its main Phase 3 goal in high-risk melanoma. The result suggests tailored vaccines may train the immune system to target each patient's tumour.
·Noida, India
Read Full Article
Moderna and US partner Merck are presenting studies for a new cancer vaccine – and thus not only nourish the imagination of investors. With mRNA, tumors could be prevented by vaccination.
·Düsseldorf, Germany
Read Full Article
They managed to prevent the recurrence and spread of melanoma in a large clinical trial, using a serum of mRNA; expectations of a new treatment pathway
·Vicente López, Argentina
Read Full Article
Moderna's actions rose more than 100%, given the advance of her personalized cancer vaccine.
·Mexico
Read Full ArticleCoverage Details
Total News Sources11
Leaning Left0Leaning Right4Center3Last UpdatedBias Distribution57% Right
Bias Distribution
- 57% of the sources lean Right
57% Right
C 43%
R 57%
Factuality
To view factuality data please Upgrade to Premium
